CSIMarket
 


Relay Therapeutics Inc   (RLAY)
Other Ticker:  
 

Cumulative Relay Therapeutics Inc 's Leverage Ratio for Trailing Twelve Months Period

RLAY's Leverage Ratio for Trailing Twelve Months Period and Total Liabilities, Equity growth


Select the Comparisons : Select the Ratio:

RLAY Leverage Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Growth -22.14 % 3.91 % -1.6 % 66.39 % 61.64 %
Y / Y Total Liabilities Growth -23.89 % 38.36 % 39.33 % 48.77 % 76.22 %
Leverage Ratio for Trailing Twelve Months Period 0.17 0.17 0.16 0.15 0.15
Total Ranking # 342 # 381 # 390 # 409 # 428
Seq. Equity Growth -3.92 % -8.3 % -7.03 % -4.96 % 28.24 %
Seq. Total Liabilities Growth -15.35 % -1.46 % 3.07 % -11.48 % 53.89 %


Leverage Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to debt repayement of -15.35% Relay Therapeutics Inc has not changed Leverage Ratio for Trailing Twelve Months Period in the III. Quarter to 0.17, below company's average Leverage Ratio for Trailing Twelve Months Period.
Leverage Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies in Biotechnology & Pharmaceuticals industry 27 other companies have achieved lower Leverage Ratio for Trailing Twelve Months Period than Relay Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. .

What is Leverage Ratio?
Who are RLAY's Customers?
Leverage Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 28
Sector # 185
S&P 500 # 327


Leverage Ratio for Trailing Twelve Months Period Statistics
High Average Low
0.36 0.18 0.07
(Dec 31 2020)   (Jun 30 2021)




Companies with similar average Leverage Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Leverage Ratio for Trailing Twelve Months Period
Recursion Pharmaceuticals Inc   0.47 
Aptose Biosciences Inc   0.46 
Bluebird Bio Inc   0.45 
Senti Biosciences Inc   0.44 
Aligos Therapeutics Inc   0.43 
Vaxart Inc   0.43 
Tcr2 Therapeutics Inc   0.42 
Genfit S a   0.42 
Inmune Bio Inc   0.41 
Neurocrine Biosciences Inc   0.40 
Cellectis S a   0.40 
Surface Oncology Inc   0.40 
Tscan Therapeutics Inc   0.38 
Moderna Inc   0.38 
Editas Medicine Inc   0.36 
Black Diamond Therapeutics Inc   0.35 
Renovacor Inc   0.35 
Pharmacyte Biotech Inc   0.34 
Polarityte Inc   0.34 
Mesoblast Ltd  0.33 
Scholar Rock Holding Corp  0.33 
Miromatrix Medical inc   0.33 
Fusion Pharmaceuticals Inc   0.31 
Cognition Therapeutics inc   0.31 
Seagen Inc   0.30 
Repligen Corp  0.30 
Monte Rosa Therapeutics Inc   0.28 
Sophia Genetics Sa  0.28 
Instil Bio Inc   0.28 
Voyager Therapeutics Inc   0.28 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com